Efficacy and Safety of Obeticholic Acid for Treating Hepatic Steatosis in Patients With Familial Partial Lipodystrophy
- 13 March 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , e3617-e3625
Abstract
Context: Patients with familial partial lipodystrophy (FPLD) have increased risk of hepatic steatosis and its complications, for which there is no approved therapy. Objective: This work aimed to investigate the efficacy and safety of obeticholic acid (OCA), a farnesoid X receptor agonist, for reducing hepatic steatosis in patients with FPLD. Methods: A randomized, double-blind, placebo-controlled, crossover trial was conducted at an academic referral center. Ten women (age 19-60 years) with the Dunnigan variety of FPLD (FPLD2), harboring pathogenic heterozygous variants in the lamin A/C gene and hepatic steatosis (liver fat >5.6% by proton-density fat fraction mapping by magnetic resonance imaging), were included. Intervention included OCA 25 mg daily vs matched placebo for 4 months each with a 4-month washout period in between. The primary end point variable was liver fat. Secondary end point variables were serum triglycerides (TGs) and transaminase levels. Results: All patients completed the trial. OCA therapy caused significant (39.6%) reduction in liver fat as compared to placebo (median liver fat [minimum-maximum]; 6.4% [2.4%-18.0%] vs 10.6% [3.4%-29.3%], respectively; P value for treatment × month interaction = .03). There were no significant differences in serum TGs or transaminase levels during OCA and placebo therapy. Overall, OCA was well tolerated except for itching in 4 patients compared to 2 on placebo. OCA, as compared to placebo, caused 24% increase in serum low-density lipoprotein cholesterol (mean 129 mg/dL vs 104 mg/dL, respectively; P = .0016). Conclusion: OCA is safe and effective in lowering hepatic TG levels in patients with FPLD2.Keywords
Funding Information
- National Center for Advancing Translational Sciences ((UL1TR001105))
- Intercept Pharmaceuticals
This publication has 58 references indexed in Scilit:
- Magnetic resonance imaging proton density fat fraction as an imaging‐based biomarker of treatment response in patients with nonalcoholic steatohepatitisClinical Liver Disease, 2022
- IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASHHepatology, 2022
- Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASHHepatology, 2020
- Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathyAmerican Journal of Medical Genetics Part A, 2016
- Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human liversHepatology, 2015
- Bile acids reach out to the spinal cord: New insights to the pathogenesis of itch and analgesia in cholestatic liver diseaseHepatology, 2013
- In vivo characterization of the liver fat 1H MR spectrumNMR in Biomedicine, 2010
- Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDECEMBO Molecular Medicine, 2009
- Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy†Hepatology, 2005
- Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trialHepatology, 2004